TY - JOUR
T1 - Interleukin-8 in cancer pathogenesis, treatment and follow-up
AU - Alfaro, Carlos
AU - Sanmamed, Miguel F.
AU - Rodríguez-Ruiz, María E.
AU - Teijeira, Álvaro
AU - Oñate, Carmen
AU - González, Álvaro
AU - Ponz, Mariano
AU - Schalper, Kurt A.
AU - Pérez-Gracia, José L.
AU - Melero, Ignacio
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/11
Y1 - 2017/11
N2 - Interleukin-8 (CXCL8) was originally described as a chemokine whose main function is the attraction of a polymorphonuclear inflammatory leukocyte infiltrate acting on CXCR1/2. Recently, it has been found that tumors very frequently coopt the production of this chemokine, which in this malignant context exerts different pro-tumoral functions. Reportedly, these include angiogenesis, survival signaling for cancer stem cells and attraction of myeloid cells endowed with the ability to immunosuppress and locally provide growth factors. Given the fact that in cancer patients IL-8 is mainly produced by tumor cells themselves, its serum concentration has been shown to correlate with tumor burden. Thus, IL-8 serum concentrations have been shown to be useful as a pharmacodynamic biomarker to early detect response to immunotherapy. Finally, because of the roles that IL-8 plays in favoring tumor progression, several therapeutic strategies are being developed to interfere with its functions. Such interventions hold promise, especially for therapeutic combinations in the field of cancer immunotherapy.
AB - Interleukin-8 (CXCL8) was originally described as a chemokine whose main function is the attraction of a polymorphonuclear inflammatory leukocyte infiltrate acting on CXCR1/2. Recently, it has been found that tumors very frequently coopt the production of this chemokine, which in this malignant context exerts different pro-tumoral functions. Reportedly, these include angiogenesis, survival signaling for cancer stem cells and attraction of myeloid cells endowed with the ability to immunosuppress and locally provide growth factors. Given the fact that in cancer patients IL-8 is mainly produced by tumor cells themselves, its serum concentration has been shown to correlate with tumor burden. Thus, IL-8 serum concentrations have been shown to be useful as a pharmacodynamic biomarker to early detect response to immunotherapy. Finally, because of the roles that IL-8 plays in favoring tumor progression, several therapeutic strategies are being developed to interfere with its functions. Such interventions hold promise, especially for therapeutic combinations in the field of cancer immunotherapy.
KW - CXCR1/2
KW - Cancer therapeutic agents
KW - IL-8 (CXCL8)
KW - Immunotherapy
KW - Myeloid-derived suppressor cells
KW - Pharmacodynamic biomarker
UR - http://www.scopus.com/inward/record.url?scp=85028567658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028567658&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2017.08.004
DO - 10.1016/j.ctrv.2017.08.004
M3 - Review article
C2 - 28866366
AN - SCOPUS:85028567658
SN - 0305-7372
VL - 60
SP - 24
EP - 31
JO - Cancer treatment reviews
JF - Cancer treatment reviews
ER -